In conclusion, the knowledge gained from our study is that HDAC inhibitors impede gastric tumor cell migration, proliferation, and suppression of other cellular functions of tumors by regulating E2F5 through direct BCL2 targeting. This evidence concerns the gene HDAC9 and gastric neoplasm.